ICON Public Limited Company (ICLR) Stock Competitors & Peer Comparison
See (ICLR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ICLR | $135.00 | -0.79% | 10.6B | 47.60 | $2.90 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.75% |
| TMO | $479.16 | -2.71% | 183.6B | 27.19 | $18.17 | +0.36% |
| DHR | $176.56 | -3.34% | 127.3B | 34.93 | $5.15 | +0.75% |
| IDXX | $554.13 | -1.67% | 44.7B | 41.74 | $13.58 | N/A |
| A | $134.18 | -1.00% | 38.4B | 27.32 | $4.98 | +0.56% |
| NTRA | $214.07 | -4.16% | 31.3B | -134.08 | -$1.63 | N/A |
| IQV | $179.68 | -1.39% | 31.2B | 23.19 | $8.06 | N/A |
| ILMN | $163.32 | +0.22% | 24.9B | 29.84 | $5.51 | N/A |
| WAT | $371.40 | -3.17% | 24.6B | 48.17 | $7.85 | N/A |
Stock Comparison
ICLR vs DHR-PB Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, ICLR is priced at $135.00, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, ICLR's ROE is +0.02%, compared to DHR-PB's ROE of +0.07%. Regarding short-term risk, ICLR is more volatile compared to DHR-PB. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check DHR-PB's competition here
ICLR vs TMO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, TMO has a market cap of 183.6B. Regarding current trading prices, ICLR is priced at $135.00, while TMO trades at $479.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas TMO's P/E ratio is 27.19. In terms of profitability, ICLR's ROE is +0.02%, compared to TMO's ROE of +0.13%. Regarding short-term risk, ICLR is more volatile compared to TMO. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check TMO's competition here
ICLR vs DHR Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DHR has a market cap of 127.3B. Regarding current trading prices, ICLR is priced at $135.00, while DHR trades at $176.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DHR's P/E ratio is 34.93. In terms of profitability, ICLR's ROE is +0.02%, compared to DHR's ROE of +0.07%. Regarding short-term risk, ICLR is more volatile compared to DHR. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check DHR's competition here
ICLR vs IDXX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, IDXX has a market cap of 44.7B. Regarding current trading prices, ICLR is priced at $135.00, while IDXX trades at $554.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas IDXX's P/E ratio is 41.74. In terms of profitability, ICLR's ROE is +0.02%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, ICLR is more volatile compared to IDXX. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check IDXX's competition here
ICLR vs A Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, A has a market cap of 38.4B. Regarding current trading prices, ICLR is priced at $135.00, while A trades at $134.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas A's P/E ratio is 27.32. In terms of profitability, ICLR's ROE is +0.02%, compared to A's ROE of +0.21%. Regarding short-term risk, ICLR is more volatile compared to A. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check A's competition here
ICLR vs NTRA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NTRA has a market cap of 31.3B. Regarding current trading prices, ICLR is priced at $135.00, while NTRA trades at $214.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NTRA's P/E ratio is -134.08. In terms of profitability, ICLR's ROE is +0.02%, compared to NTRA's ROE of -0.15%. Regarding short-term risk, ICLR is more volatile compared to NTRA. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check NTRA's competition here
ICLR vs IQV Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, IQV has a market cap of 31.2B. Regarding current trading prices, ICLR is priced at $135.00, while IQV trades at $179.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas IQV's P/E ratio is 23.19. In terms of profitability, ICLR's ROE is +0.02%, compared to IQV's ROE of +0.22%. Regarding short-term risk, ICLR is more volatile compared to IQV. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check IQV's competition here
ICLR vs ILMN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ILMN has a market cap of 24.9B. Regarding current trading prices, ICLR is priced at $135.00, while ILMN trades at $163.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ILMN's P/E ratio is 29.84. In terms of profitability, ICLR's ROE is +0.02%, compared to ILMN's ROE of +0.34%. Regarding short-term risk, ICLR is more volatile compared to ILMN. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check ILMN's competition here
ICLR vs WAT Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, WAT has a market cap of 24.6B. Regarding current trading prices, ICLR is priced at $135.00, while WAT trades at $371.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas WAT's P/E ratio is 48.17. In terms of profitability, ICLR's ROE is +0.02%, compared to WAT's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to WAT. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check WAT's competition here
ICLR vs MTD Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MTD has a market cap of 23.9B. Regarding current trading prices, ICLR is priced at $135.00, while MTD trades at $1,159.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MTD's P/E ratio is 27.77. In terms of profitability, ICLR's ROE is +0.02%, compared to MTD's ROE of -6.10%. Regarding short-term risk, ICLR is more volatile compared to MTD. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check MTD's competition here
ICLR vs DGX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DGX has a market cap of 21.3B. Regarding current trading prices, ICLR is priced at $135.00, while DGX trades at $192.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DGX's P/E ratio is 21.26. In terms of profitability, ICLR's ROE is +0.02%, compared to DGX's ROE of +0.14%. Regarding short-term risk, ICLR is more volatile compared to DGX. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check DGX's competition here
ICLR vs LH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, LH has a market cap of 21.1B. Regarding current trading prices, ICLR is priced at $135.00, while LH trades at $256.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas LH's P/E ratio is 22.75. In terms of profitability, ICLR's ROE is +0.02%, compared to LH's ROE of +0.11%. Regarding short-term risk, ICLR is more volatile compared to LH. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check LH's competition here
ICLR vs EXAS Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, ICLR is priced at $135.00, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas EXAS's P/E ratio is -95.37. In terms of profitability, ICLR's ROE is +0.02%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, ICLR is more volatile compared to EXAS. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check EXAS's competition here
ICLR vs GH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, GH has a market cap of 17.1B. Regarding current trading prices, ICLR is priced at $135.00, while GH trades at $129.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas GH's P/E ratio is -38.09. In terms of profitability, ICLR's ROE is +0.02%, compared to GH's ROE of +1.84%. Regarding short-term risk, ICLR is more volatile compared to GH. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check GH's competition here
ICLR vs PKI Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, ICLR is priced at $135.00, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PKI's P/E ratio is 41.45. In terms of profitability, ICLR's ROE is +0.02%, compared to PKI's ROE of +0.03%. Regarding short-term risk, ICLR is more volatile compared to PKI. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check PKI's competition here
ICLR vs MEDP Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MEDP has a market cap of 12.9B. Regarding current trading prices, ICLR is priced at $135.00, while MEDP trades at $441.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MEDP's P/E ratio is 28.45. In terms of profitability, ICLR's ROE is +0.02%, compared to MEDP's ROE of +1.21%. Regarding short-term risk, ICLR is more volatile compared to MEDP. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check MEDP's competition here
ICLR vs RVTY Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, RVTY has a market cap of 11.2B. Regarding current trading prices, ICLR is priced at $135.00, while RVTY trades at $99.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas RVTY's P/E ratio is 48.33. In terms of profitability, ICLR's ROE is +0.02%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, ICLR is more volatile compared to RVTY. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check RVTY's competition here
ICLR vs CRL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CRL has a market cap of 8.8B. Regarding current trading prices, ICLR is priced at $135.00, while CRL trades at $173.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CRL's P/E ratio is -49.24. In terms of profitability, ICLR's ROE is +0.02%, compared to CRL's ROE of -0.06%. Regarding short-term risk, ICLR is more volatile compared to CRL. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CRL's competition here
ICLR vs QGEN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, QGEN has a market cap of 7.5B. Regarding current trading prices, ICLR is priced at $135.00, while QGEN trades at $35.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas QGEN's P/E ratio is 18.46. In terms of profitability, ICLR's ROE is +0.02%, compared to QGEN's ROE of +0.11%. Regarding short-term risk, ICLR is more volatile compared to QGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check QGEN's competition here
ICLR vs SYNH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, ICLR is priced at $135.00, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas SYNH's P/E ratio is 61.40. In terms of profitability, ICLR's ROE is +0.02%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, ICLR is more volatile compared to SYNH. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check SYNH's competition here
ICLR vs SHC Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, SHC has a market cap of 4.4B. Regarding current trading prices, ICLR is priced at $135.00, while SHC trades at $14.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas SHC's P/E ratio is 37.90. In terms of profitability, ICLR's ROE is +0.02%, compared to SHC's ROE of +0.21%. Regarding short-term risk, ICLR is more volatile compared to SHC. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check SHC's competition here
ICLR vs TWST Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, TWST has a market cap of 4.2B. Regarding current trading prices, ICLR is priced at $135.00, while TWST trades at $69.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas TWST's P/E ratio is -51.41. In terms of profitability, ICLR's ROE is +0.02%, compared to TWST's ROE of -0.17%. Regarding short-term risk, ICLR is more volatile compared to TWST. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check TWST's competition here
ICLR vs BLLN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BLLN has a market cap of 4.2B. Regarding current trading prices, ICLR is priced at $135.00, while BLLN trades at $94.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BLLN's P/E ratio is 168.74. In terms of profitability, ICLR's ROE is +0.02%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, ICLR is less volatile compared to BLLN. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BLLN's competition here
ICLR vs RDNT Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, RDNT has a market cap of 4.2B. Regarding current trading prices, ICLR is priced at $135.00, while RDNT trades at $54.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas RDNT's P/E ratio is -311.12. In terms of profitability, ICLR's ROE is +0.02%, compared to RDNT's ROE of -0.01%. Regarding short-term risk, ICLR is more volatile compared to RDNT. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check RDNT's competition here
ICLR vs OLK Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, ICLR is priced at $135.00, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas OLK's P/E ratio is -96.59. In terms of profitability, ICLR's ROE is +0.02%, compared to OLK's ROE of -0.07%. Regarding short-term risk, ICLR is more volatile compared to OLK. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check OLK's competition here
ICLR vs GRAL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, GRAL has a market cap of 2.8B. Regarding current trading prices, ICLR is priced at $135.00, while GRAL trades at $60.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas GRAL's P/E ratio is -6.25. In terms of profitability, ICLR's ROE is +0.02%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, ICLR is less volatile compared to GRAL. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check GRAL's competition here
ICLR vs NEOG Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NEOG has a market cap of 1.9B. Regarding current trading prices, ICLR is priced at $135.00, while NEOG trades at $8.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NEOG's P/E ratio is -3.19. In terms of profitability, ICLR's ROE is +0.02%, compared to NEOG's ROE of -0.29%. Regarding short-term risk, ICLR is more volatile compared to NEOG. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check NEOG's competition here
ICLR vs CDNA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CDNA has a market cap of 1.2B. Regarding current trading prices, ICLR is priced at $135.00, while CDNA trades at $22.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CDNA's P/E ratio is -142.50. In terms of profitability, ICLR's ROE is +0.02%, compared to CDNA's ROE of -0.03%. Regarding short-term risk, ICLR is more volatile compared to CDNA. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CDNA's competition here
ICLR vs PSNL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PSNL has a market cap of 999.9M. Regarding current trading prices, ICLR is priced at $135.00, while PSNL trades at $11.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PSNL's P/E ratio is -11.04. In terms of profitability, ICLR's ROE is +0.02%, compared to PSNL's ROE of -0.44%. Regarding short-term risk, ICLR is more volatile compared to PSNL. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check PSNL's competition here
ICLR vs CSTL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CSTL has a market cap of 636M. Regarding current trading prices, ICLR is priced at $135.00, while CSTL trades at $19.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CSTL's P/E ratio is -49.93. In terms of profitability, ICLR's ROE is +0.02%, compared to CSTL's ROE of -0.03%. Regarding short-term risk, ICLR is more volatile compared to CSTL. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CSTL's competition here
ICLR vs GRALV Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, ICLR is priced at $135.00, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas GRALV's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to GRALV's ROE of N/A. Regarding short-term risk, ICLR is less volatile compared to GRALV. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check GRALV's competition here
ICLR vs FLGT Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, FLGT has a market cap of 513.8M. Regarding current trading prices, ICLR is priced at $135.00, while FLGT trades at $18.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas FLGT's P/E ratio is -7.54. In terms of profitability, ICLR's ROE is +0.02%, compared to FLGT's ROE of -0.07%. Regarding short-term risk, ICLR is more volatile compared to FLGT. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check FLGT's competition here
ICLR vs MYGN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MYGN has a market cap of 404.2M. Regarding current trading prices, ICLR is priced at $135.00, while MYGN trades at $4.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MYGN's P/E ratio is -0.99. In terms of profitability, ICLR's ROE is +0.02%, compared to MYGN's ROE of -1.09%. Regarding short-term risk, ICLR is less volatile compared to MYGN. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check MYGN's competition here
ICLR vs CO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, ICLR is priced at $135.00, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CO's P/E ratio is 5.06. In terms of profitability, ICLR's ROE is +0.02%, compared to CO's ROE of +0.11%. Regarding short-term risk, ICLR is less volatile compared to CO. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check CO's competition here
ICLR vs PRE Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PRE has a market cap of 346.6M. Regarding current trading prices, ICLR is priced at $135.00, while PRE trades at $20.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PRE's P/E ratio is -8.29. In terms of profitability, ICLR's ROE is +0.02%, compared to PRE's ROE of -0.36%. Regarding short-term risk, ICLR is less volatile compared to PRE. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check PRE's competition here
ICLR vs FLDM Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, ICLR is priced at $135.00, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas FLDM's P/E ratio is -4.74. In terms of profitability, ICLR's ROE is +0.02%, compared to FLDM's ROE of +0.17%. Regarding short-term risk, ICLR is less volatile compared to FLDM. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check FLDM's competition here
ICLR vs NEO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NEO has a market cap of 271.9M. Regarding current trading prices, ICLR is priced at $135.00, while NEO trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NEO's P/E ratio is -13.56. In terms of profitability, ICLR's ROE is +0.02%, compared to NEO's ROE of -0.12%. Regarding short-term risk, ICLR is more volatile compared to NEO. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check NEO's competition here
ICLR vs OPGN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, OPGN has a market cap of 242.7M. Regarding current trading prices, ICLR is priced at $135.00, while OPGN trades at $23.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas OPGN's P/E ratio is 132.83. In terms of profitability, ICLR's ROE is +0.02%, compared to OPGN's ROE of +1.58%. Regarding short-term risk, ICLR is more volatile compared to OPGN. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check OPGN's competition here
ICLR vs IMDX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, IMDX has a market cap of 165.3M. Regarding current trading prices, ICLR is priced at $135.00, while IMDX trades at $6.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas IMDX's P/E ratio is -4.08. In terms of profitability, ICLR's ROE is +0.02%, compared to IMDX's ROE of +3.81%. Regarding short-term risk, ICLR is less volatile compared to IMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check IMDX's competition here
ICLR vs XGN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, XGN has a market cap of 129.3M. Regarding current trading prices, ICLR is priced at $135.00, while XGN trades at $4.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas XGN's P/E ratio is -5.94. In terms of profitability, ICLR's ROE is +0.02%, compared to XGN's ROE of -1.14%. Regarding short-term risk, ICLR is less volatile compared to XGN. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check XGN's competition here
ICLR vs GTH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, ICLR is priced at $135.00, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas GTH's P/E ratio is -1.11. In terms of profitability, ICLR's ROE is +0.02%, compared to GTH's ROE of -1.01%. Regarding short-term risk, ICLR is more volatile compared to GTH. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check GTH's competition here
ICLR vs BDSX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BDSX has a market cap of 124.3M. Regarding current trading prices, ICLR is priced at $135.00, while BDSX trades at $15.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BDSX's P/E ratio is -3.86. In terms of profitability, ICLR's ROE is +0.02%, compared to BDSX's ROE of -21.01%. Regarding short-term risk, ICLR is more volatile compared to BDSX. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check BDSX's competition here
ICLR vs STIM Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, STIM has a market cap of 116.2M. Regarding current trading prices, ICLR is priced at $135.00, while STIM trades at $1.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas STIM's P/E ratio is -3.09. In terms of profitability, ICLR's ROE is +0.02%, compared to STIM's ROE of -1.65%. Regarding short-term risk, ICLR is less volatile compared to STIM. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check STIM's competition here
ICLR vs ATLN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ATLN has a market cap of 115.9M. Regarding current trading prices, ICLR is priced at $135.00, while ATLN trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ATLN's P/E ratio is -1.35. In terms of profitability, ICLR's ROE is +0.02%, compared to ATLN's ROE of +2.74%. Regarding short-term risk, ICLR is more volatile compared to ATLN. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check ATLN's competition here
ICLR vs GENE Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, ICLR is priced at $135.00, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas GENE's P/E ratio is -38.25. In terms of profitability, ICLR's ROE is +0.02%, compared to GENE's ROE of -1.85%. Regarding short-term risk, ICLR is more volatile compared to GENE. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check GENE's competition here
ICLR vs SERA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, SERA has a market cap of 83.6M. Regarding current trading prices, ICLR is priced at $135.00, while SERA trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas SERA's P/E ratio is -3.42. In terms of profitability, ICLR's ROE is +0.02%, compared to SERA's ROE of -0.41%. Regarding short-term risk, ICLR is less volatile compared to SERA. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check SERA's competition here
ICLR vs DRIO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DRIO has a market cap of 56.3M. Regarding current trading prices, ICLR is priced at $135.00, while DRIO trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DRIO's P/E ratio is -0.91. In terms of profitability, ICLR's ROE is +0.02%, compared to DRIO's ROE of +0.93%. Regarding short-term risk, ICLR is less volatile compared to DRIO. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check DRIO's competition here
ICLR vs STRR Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, STRR has a market cap of 43.3M. Regarding current trading prices, ICLR is priced at $135.00, while STRR trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas STRR's P/E ratio is -4.68. In terms of profitability, ICLR's ROE is +0.02%, compared to STRR's ROE of -0.14%. Regarding short-term risk, ICLR is less volatile compared to STRR. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check STRR's competition here
ICLR vs PRPO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PRPO has a market cap of 40.3M. Regarding current trading prices, ICLR is priced at $135.00, while PRPO trades at $23.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PRPO's P/E ratio is -50.07. In terms of profitability, ICLR's ROE is +0.02%, compared to PRPO's ROE of -0.07%. Regarding short-term risk, ICLR is more volatile compared to PRPO. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check PRPO's competition here
ICLR vs MDXH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MDXH has a market cap of 33.9M. Regarding current trading prices, ICLR is priced at $135.00, while MDXH trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MDXH's P/E ratio is -1.02. In terms of profitability, ICLR's ROE is +0.02%, compared to MDXH's ROE of +4.03%. Regarding short-term risk, ICLR is less volatile compared to MDXH. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check MDXH's competition here
ICLR vs STRRP Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, STRRP has a market cap of 33.2M. Regarding current trading prices, ICLR is priced at $135.00, while STRRP trades at $9.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas STRRP's P/E ratio is -4.91. In terms of profitability, ICLR's ROE is +0.02%, compared to STRRP's ROE of -0.14%. Regarding short-term risk, ICLR is more volatile compared to STRRP. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check STRRP's competition here
ICLR vs QUCY Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, QUCY has a market cap of 27.9M. Regarding current trading prices, ICLR is priced at $135.00, while QUCY trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas QUCY's P/E ratio is -0.10. In terms of profitability, ICLR's ROE is +0.02%, compared to QUCY's ROE of -2.44%. Regarding short-term risk, ICLR is less volatile compared to QUCY. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check QUCY's competition here
ICLR vs AKU Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, ICLR is priced at $135.00, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas AKU's P/E ratio is -0.13. In terms of profitability, ICLR's ROE is +0.02%, compared to AKU's ROE of -5.32%. Regarding short-term risk, ICLR is less volatile compared to AKU. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check AKU's competition here
ICLR vs CEMI Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, ICLR is priced at $135.00, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CEMI's P/E ratio is -0.63. In terms of profitability, ICLR's ROE is +0.02%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, ICLR is more volatile compared to CEMI. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CEMI's competition here
ICLR vs ENZ Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, ICLR is priced at $135.00, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ENZ's P/E ratio is -2.85. In terms of profitability, ICLR's ROE is +0.02%, compared to ENZ's ROE of -0.10%. Regarding short-term risk, ICLR is less volatile compared to ENZ. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check ENZ's competition here
ICLR vs PMD Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, ICLR is priced at $135.00, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PMD's P/E ratio is -5.24. In terms of profitability, ICLR's ROE is +0.02%, compared to PMD's ROE of -0.32%. Regarding short-term risk, ICLR is more volatile compared to PMD. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check PMD's competition here
ICLR vs ME Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, ICLR is priced at $135.00, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ME's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.02%, compared to ME's ROE of -7.71%. Regarding short-term risk, ICLR is more volatile compared to ME. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check ME's competition here
ICLR vs MYNZ Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, ICLR is priced at $135.00, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, ICLR's ROE is +0.02%, compared to MYNZ's ROE of -10.25%. Regarding short-term risk, ICLR is less volatile compared to MYNZ. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check MYNZ's competition here
ICLR vs VNRX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, VNRX has a market cap of 14.1M. Regarding current trading prices, ICLR is priced at $135.00, while VNRX trades at $2.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas VNRX's P/E ratio is -0.62. In terms of profitability, ICLR's ROE is +0.02%, compared to VNRX's ROE of +0.74%. Regarding short-term risk, ICLR is less volatile compared to VNRX. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check VNRX's competition here
ICLR vs CHEK Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, ICLR is priced at $135.00, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CHEK's P/E ratio is -0.43. In terms of profitability, ICLR's ROE is +0.02%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, ICLR is more volatile compared to CHEK. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CHEK's competition here
ICLR vs NOTV Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NOTV has a market cap of 10.7M. Regarding current trading prices, ICLR is priced at $135.00, while NOTV trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NOTV's P/E ratio is -0.12. In terms of profitability, ICLR's ROE is +0.02%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, ICLR is less volatile compared to NOTV. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check NOTV's competition here
ICLR vs MBAI Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MBAI has a market cap of 10.2M. Regarding current trading prices, ICLR is priced at $135.00, while MBAI trades at $1.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MBAI's P/E ratio is 2.64. In terms of profitability, ICLR's ROE is +0.02%, compared to MBAI's ROE of +4.17%. Regarding short-term risk, ICLR is more volatile compared to MBAI. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check MBAI's competition here
ICLR vs CNTG Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, ICLR is priced at $135.00, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CNTG's P/E ratio is -0.23. In terms of profitability, ICLR's ROE is +0.02%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, ICLR is more volatile compared to CNTG. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check CNTG's competition here
ICLR vs BNR Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BNR has a market cap of 9.3M. Regarding current trading prices, ICLR is priced at $135.00, while BNR trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BNR's P/E ratio is -11.38. In terms of profitability, ICLR's ROE is +0.02%, compared to BNR's ROE of -0.10%. Regarding short-term risk, ICLR is less volatile compared to BNR. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BNR's competition here
ICLR vs BIAF Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BIAF has a market cap of 7.9M. Regarding current trading prices, ICLR is priced at $135.00, while BIAF trades at $1.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BIAF's P/E ratio is -0.37. In terms of profitability, ICLR's ROE is +0.02%, compared to BIAF's ROE of -3.59%. Regarding short-term risk, ICLR is less volatile compared to BIAF. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BIAF's competition here
ICLR vs TRIB Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, TRIB has a market cap of 7.3M. Regarding current trading prices, ICLR is priced at $135.00, while TRIB trades at $0.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas TRIB's P/E ratio is -0.35. In terms of profitability, ICLR's ROE is +0.02%, compared to TRIB's ROE of +0.68%. Regarding short-term risk, ICLR is more volatile compared to TRIB. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check TRIB's competition here
ICLR vs APDN Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, ICLR is priced at $135.00, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas APDN's P/E ratio is -0.10. In terms of profitability, ICLR's ROE is +0.02%, compared to APDN's ROE of -6.53%. Regarding short-term risk, ICLR is less volatile compared to APDN. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check APDN's competition here
ICLR vs NVTA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, ICLR is priced at $135.00, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NVTA's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.02%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, ICLR is less volatile compared to NVTA. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check NVTA's competition here
ICLR vs LMDX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, ICLR is priced at $135.00, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas LMDX's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.02%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, ICLR is less volatile compared to LMDX. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check LMDX's competition here
ICLR vs LMDXW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, ICLR is priced at $135.00, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, ICLR's ROE is +0.02%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, ICLR is less volatile compared to LMDXW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check LMDXW's competition here
ICLR vs ADVB Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ADVB has a market cap of 4.7M. Regarding current trading prices, ICLR is priced at $135.00, while ADVB trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ADVB's P/E ratio is 1.09. In terms of profitability, ICLR's ROE is +0.02%, compared to ADVB's ROE of -0.20%. Regarding short-term risk, ICLR is less volatile compared to ADVB. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check ADVB's competition here
ICLR vs BGLC Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BGLC has a market cap of 4.5M. Regarding current trading prices, ICLR is priced at $135.00, while BGLC trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BGLC's P/E ratio is -1.50. In terms of profitability, ICLR's ROE is +0.02%, compared to BGLC's ROE of -0.37%. Regarding short-term risk, ICLR is less volatile compared to BGLC. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BGLC's competition here
ICLR vs NDRA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NDRA has a market cap of 4.2M. Regarding current trading prices, ICLR is priced at $135.00, while NDRA trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NDRA's P/E ratio is -0.69. In terms of profitability, ICLR's ROE is +0.02%, compared to NDRA's ROE of -5.13%. Regarding short-term risk, ICLR is less volatile compared to NDRA. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check NDRA's competition here
ICLR vs BNGO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BNGO has a market cap of 4.1M. Regarding current trading prices, ICLR is priced at $135.00, while BNGO trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BNGO's P/E ratio is -0.28. In terms of profitability, ICLR's ROE is +0.02%, compared to BNGO's ROE of -0.71%. Regarding short-term risk, ICLR is more volatile compared to BNGO. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check BNGO's competition here
ICLR vs DMTK Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, ICLR is priced at $135.00, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DMTK's P/E ratio is -0.04. In terms of profitability, ICLR's ROE is +0.02%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, ICLR is less volatile compared to DMTK. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check DMTK's competition here
ICLR vs SQL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, ICLR is priced at $135.00, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas SQL's P/E ratio is -0.40. In terms of profitability, ICLR's ROE is +0.02%, compared to SQL's ROE of +2.74%. Regarding short-term risk, ICLR is less volatile compared to SQL. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check SQL's competition here
ICLR vs AWH Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, ICLR is priced at $135.00, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas AWH's P/E ratio is -0.09. In terms of profitability, ICLR's ROE is +0.02%, compared to AWH's ROE of +2.03%. Regarding short-term risk, ICLR is more volatile compared to AWH. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check AWH's competition here
ICLR vs INBS Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, INBS has a market cap of 1.6M. Regarding current trading prices, ICLR is priced at $135.00, while INBS trades at $2.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas INBS's P/E ratio is -0.21. In terms of profitability, ICLR's ROE is +0.02%, compared to INBS's ROE of -1.74%. Regarding short-term risk, ICLR is more volatile compared to INBS. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check INBS's competition here
ICLR vs HTGM Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, ICLR is priced at $135.00, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas HTGM's P/E ratio is -0.03. In terms of profitability, ICLR's ROE is +0.02%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, ICLR is more volatile compared to HTGM. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check HTGM's competition here
ICLR vs BIAFW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BIAFW has a market cap of 899.4K. Regarding current trading prices, ICLR is priced at $135.00, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BIAFW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, ICLR is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check BIAFW's competition here
ICLR vs ISPC Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, ISPC has a market cap of 463.8K. Regarding current trading prices, ICLR is priced at $135.00, while ISPC trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas ISPC's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.02%, compared to ISPC's ROE of -5.85%. Regarding short-term risk, ICLR is less volatile compared to ISPC. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check ISPC's competition here
ICLR vs BIOC Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, ICLR is priced at $135.00, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BIOC's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.02%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, ICLR is less volatile compared to BIOC. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BIOC's competition here
ICLR vs PRENW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PRENW has a market cap of 202.3K. Regarding current trading prices, ICLR is priced at $135.00, while PRENW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PRENW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to PRENW's ROE of -0.36%. Regarding short-term risk, ICLR is less volatile compared to PRENW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check PRENW's competition here
ICLR vs SQLLW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, SQLLW has a market cap of 164.5K. Regarding current trading prices, ICLR is priced at $135.00, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas SQLLW's P/E ratio is -0.01. In terms of profitability, ICLR's ROE is +0.02%, compared to SQLLW's ROE of +2.74%. Regarding short-term risk, ICLR is less volatile compared to SQLLW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check SQLLW's competition here
ICLR vs TTOO Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, TTOO has a market cap of 56.1K. Regarding current trading prices, ICLR is priced at $135.00, while TTOO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas TTOO's P/E ratio is -0.07. In terms of profitability, ICLR's ROE is +0.02%, compared to TTOO's ROE of +1.47%. Regarding short-term risk, ICLR is more volatile compared to TTOO. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check TTOO's competition here
ICLR vs OCDX Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas OCDX's P/E ratio is -42.28. In terms of profitability, ICLR's ROE is +0.02%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, ICLR is more volatile compared to OCDX. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check OCDX's competition here
ICLR vs NDRAW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas NDRAW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to NDRAW's ROE of -5.13%. Regarding short-term risk, ICLR is less volatile compared to NDRAW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check NDRAW's competition here
ICLR vs PRXL Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas PRXL's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, ICLR is more volatile compared to PRXL. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check PRXL's competition here
ICLR vs MEUSW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas MEUSW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to MEUSW's ROE of -7.71%. Regarding short-term risk, ICLR is less volatile compared to MEUSW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check MEUSW's competition here
ICLR vs CHEKZ Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, ICLR is less volatile compared to CHEKZ. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check CHEKZ's competition here
ICLR vs BNGOW Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas BNGOW's P/E ratio is N/A. In terms of profitability, ICLR's ROE is +0.02%, compared to BNGOW's ROE of -0.71%. Regarding short-term risk, ICLR is less volatile compared to BNGOW. This indicates potentially lower risk in terms of short-term price fluctuations for ICLR.Check BNGOW's competition here
ICLR vs DHR-PA Comparison June 2026
ICLR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ICLR stands at 10.6B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, ICLR is priced at $135.00, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ICLR currently has a P/E ratio of 47.60, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, ICLR's ROE is +0.02%, compared to DHR-PA's ROE of +0.07%. Regarding short-term risk, ICLR is more volatile compared to DHR-PA. This indicates potentially higher risk in terms of short-term price fluctuations for ICLR.Check DHR-PA's competition here